Truist Financial Corp increased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 21.0% during the 4th quarter, according to its most recent disclosure with the SEC. The ...

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations. Looking ...

Fintel reports that on February 28, 2025, Barrington Research downgraded their outlook for LeMaitre Vascular (NasdaqGM:LMAT) ...

Oppenheimer has downgraded LeMaitre Vascular (NASDAQ:LMAT) to perform from outperform as its price target of $93 has been met ...

Barrington analyst Michael Petusky downgraded LeMaitre (LMAT) to Market Perform from Outperform without a price target following the Q4 report.

Citizens JMP raised the firm’s price target on LeMaitre (LMAT) to $113 from $100 and keeps an Outperform rating on the shares. LeMaitre’s Q4 ...

For the current quarter ending in March, LeMaitre said it expects revenue in the range of $56.7 million to $58.7 million. The company expects full-year earnings to be $2.15 to $2.32 per share, with ...

Medical device company LeMaitre Vascular (NASDAQ:LMAT) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose ...

Everybody dreams of playing for Toulouse. But what is the story of Melvyn Jaminet, a €450,000 loan and a potential salary cap ...

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) will likely be releasing its earnings data after the market closes on ...

Learn more about whether LeMaitre Vascular, Inc. or Neogen Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.